Since 1888, the U.S. has published weekly reports on cases of notifiable diseases, building a huge trove of data in the process. The usefulness of this data was limited by its format, which stopped researchers from effectively mining it for insights, but a massive digitization project has now opened up the information.
NextBio was set up to solve a problem partly created by Illumina's success in next-generation sequencing--how to make Big Data accessible and useful to researchers. Now, Illumina is to offer its own solution by acquiring NextBio and combining it with its BaseSpace cloud computing environment.
When President Obama unveiled the BRAIN Initiative in April, his speech was heavy on lofty rhetoric but light on detail. This week the team tasked with turning the grand vision into practical projects filed its first report, and placed strong emphasis on improving data storage, analysis and interpretation.
BGI is reportedly in the hunt for an initial public offering of its institutional client business. Forbes reported the IPO plan in a broader profile of the Chinese company.
Bina Technologies has added whole exome analysis to its Big Data genomics platform. The new tool can run a whole exome analysis in 30 minutes.
The National Institutes of Health has announced funding for scientists to derive knowledge from complex Big Data in biomedicine. The U.S. agency has committed $24 million per year in funding for four years, providing a $96 million pot to help fuel 6 to 8 centers of excellence.
Boehringer Ingelheim has become one of the latest large drugmakers to deepen its commitment to mining massive datasets in its R&D operations. In a plug for the software group's Big Data technology, NextBio touted that Boehringer had renewed its agreement to use its research platform in an expanded capacity.
AstraZeneca has again turned to a software startup to aid its drug research. Cambridge, U.K.-based Optibrium scored a licensing deal form the British drug giant, which has decided to adopt the small company's StarDrop software for hunting down pharma compounds for development.
When ex-Google ($GOOG) guys Nat Turner and Zach Weinberg discussed their oncology-focused startup Flatiron Health in August they were big on ambition but low on details.
The endorsement comes as San Francisco-based Rock Health announces a new class of 11 startups for its accelerator program, which provides access to guidance, financing and experts to help the young operations succeed.